On this page of StockholderLetter.com we present the latest annual shareholder letter from CRISPR Therapeutics AG — ticker symbol CRSP. Reading current and past CRSP letters to shareholders can bring important insights into the investment thesis.
Transformative Gene-Based Medicines For Serious Human Diseases 2024 AN N UA L R E P O RT
We are rapidly translating the revolutionary CRISPR technology into therapies to treat a broad range of serious human diseases.
 • shareholder letter icon 4/16/2025 Letter Continued (Full PDF)
 • stockholder letter icon 4/26/2023 CRSP Stockholder Letter
 • stockholder letter icon 4/9/2024 CRSP Stockholder Letter
 • stockholder letter icon More "Biotechnology" Category Stockholder Letters
 • Benford's Law Stocks icon CRSP Benford's Law Stock Score = 63


CRSP Shareholder/Stockholder Letter Transcript:

Transformative Gene-Based Medicines
For Serious Human Diseases
2024 AN N UA L R E P O RT

We are rapidly translating the
revolutionary CRISPR technology
into therapies to treat a broad range
of serious human diseases.



shareholder letter icon 4/16/2025 Letter Continued (Full PDF)
 

CRSP Stockholder/Shareholder Letter (CRISPR Therapeutics AG) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.